IP Library Granted Patent US 11,730,729
Granted Patent B2
US 11,730,729 · App. 17/401,371 · Granted Aug 22, 2023

Quinolines that modulate SERCA and their use for treating disease

Inventor: Russell Dahl (Saint John, IN)
Assignee: Neurodon Corporation
A61K31/4706A61K31/4709A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,729
App. No.
17/401,371
Granted
Aug 22, 2023
Kind
B2
Abstract

Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Claims (7)

1. A pharmaceutical composition in a solid form comprising:

i) a therapeutically effective amount of a compound of the following structural formula:

or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and

ii) a pharmaceutically acceptable carrier, excipient or diluent.

2. A method for treating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1 .

3. The method of claim 2 wherein the diabetes is type 1.

4. The method of claim 2 wherein the diabetes is type 2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2021
From: DAHL, RUSSELL
To: NEURODON CORPORATION
Reel/Frame 057193/0350 →
Continuity (2)
Continuation In Part 16932832 · Jul 20, 2020
Related Publication 20220016108A1 · Jan 20, 2022